Show simple item record

dc.contributor.authorAl-Abboodi, Yasir
dc.contributor.authorRidha, Ali
dc.contributor.authorFasullo, Matthew J.
dc.contributor.authorNaguib, Tarek H.
dc.date2022-08-11T08:09:48.000
dc.date.accessioned2022-08-23T16:44:10Z
dc.date.available2022-08-23T16:44:10Z
dc.date.issued2017-09-01
dc.date.submitted2018-02-01
dc.identifier.citation<p>Clin Exp Gastroenterol. 2017 Sep 1;10:211-214. doi: 10.2147/CEG.S142644. eCollection 2017. <a href="https://doi.org/10.2147/CEG.S142644">Link to article on publisher's site</a></p>
dc.identifier.issn1178-7023 (Linking)
dc.identifier.doi10.2147/CEG.S142644
dc.identifier.pmid28979154
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40449
dc.description.abstractThis study examined the safety of placing percutaneous endoscopic gastrostomy (PEG) tube in people with liver cirrhosis. The target population was further subdivided into people with ascites (case group) and people without ascites (control). We compare the morbidity and the mortality difference of PEG placement in cirrhotic patients with ascites vs cirrhotic patients without ascites. We then examined multiple factors including sex, race, chronic illness including hypertension, congestive heart failure, and others and their influence on the inpatient mortality of all cirrhotic patients who had PEG placement. A total of 38,175 inpatient PEG tube placements were identified. Only 583 patients out of 38,175 had a history of cirrhosis. One hundred seven had ascites and the rest did not. Mean age of the patients was 61.14 years. Patient demography included (65.2%) male and the rest were female, 359 were white (64.4%), 90 black (14.8%), 84 Hispanic (13.7%), 23 Asians (3.3%), 7 Native Americans (0.4%), and 20 others (3.5%). Complications from PEG procedure in cirrhosis with ascites vs non-ascites included bleeding of 4 (0.8%) vs 2 (1.9%) (P=0.35), surgical site infection 2 (0.4%) vs 1 (0.9%) (P=0.51), and urinary tract infection 105 (22.1%) vs 34 (23.8%) (P=0.34), respectively. There was no colonic injury in either group. The total inpatient mortality was 75 out of the 583. Fifty-six (11.8%) were in the ascites group and 19 (17.8%) in the non-ascites group (P=0.097). Factors including ascites, postsurgical bleeding, and surgical site infection did not have influence on the inpatient mortality and there were no statistical differences between the two groups.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28979154&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© 2017 Al-Abboodi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/
dc.subjectascites
dc.subjectdysphagia
dc.subjectgastrointestinal
dc.subjectpercutaneous endoscopic gastrostomy
dc.subjectDigestive System Diseases
dc.subjectGastroenterology
dc.subjectPathological Conditions, Signs and Symptoms
dc.subjectSurgical Procedures, Operative
dc.titleRisks of PEG tube placement in patients with cirrhosis-associated ascites
dc.typeJournal Article
dc.source.journaltitleClinical and experimental gastroenterology
dc.source.volume10
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4263&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3253
dc.identifier.contextkey11461556
refterms.dateFOA2022-08-23T16:44:10Z
html.description.abstract<p>This study examined the safety of placing percutaneous endoscopic gastrostomy (PEG) tube in people with liver cirrhosis. The target population was further subdivided into people with ascites (case group) and people without ascites (control). We compare the morbidity and the mortality difference of PEG placement in cirrhotic patients with ascites vs cirrhotic patients without ascites. We then examined multiple factors including sex, race, chronic illness including hypertension, congestive heart failure, and others and their influence on the inpatient mortality of all cirrhotic patients who had PEG placement. A total of 38,175 inpatient PEG tube placements were identified. Only 583 patients out of 38,175 had a history of cirrhosis. One hundred seven had ascites and the rest did not. Mean age of the patients was 61.14 years. Patient demography included (65.2%) male and the rest were female, 359 were white (64.4%), 90 black (14.8%), 84 Hispanic (13.7%), 23 Asians (3.3%), 7 Native Americans (0.4%), and 20 others (3.5%). Complications from PEG procedure in cirrhosis with ascites vs non-ascites included bleeding of 4 (0.8%) vs 2 (1.9%) (P=0.35), surgical site infection 2 (0.4%) vs 1 (0.9%) (P=0.51), and urinary tract infection 105 (22.1%) vs 34 (23.8%) (P=0.34), respectively. There was no colonic injury in either group. The total inpatient mortality was 75 out of the 583. Fifty-six (11.8%) were in the ascites group and 19 (17.8%) in the non-ascites group (P=0.097). Factors including ascites, postsurgical bleeding, and surgical site infection did not have influence on the inpatient mortality and there were no statistical differences between the two groups.</p>
dc.identifier.submissionpathoapubs/3253
dc.contributor.departmentGraduate Medical Education
dc.contributor.departmentInternal Medicine Department, UMass Memorial Medical Center
dc.source.pages211-214


Files in this item

Thumbnail
Name:
CEG_142644_risks_of_peg_tube_p ...
Size:
131.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2017 Al-Abboodi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Except where otherwise noted, this item's license is described as © 2017 Al-Abboodi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).